4.5 Article

No effects of COVID-19 on the development of type 1 diabetes autoimmunity and no evidence of an increased frequency of SARS-CoV-2 antibodies in newly diagnosed type 1 diabetes patients relative to healthy subjects

期刊

ACTA DIABETOLOGICA
卷 60, 期 10, 页码 1301-1307

出版社

SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s00592-023-02103-1

关键词

COVID-19; SARS-CoV-2; SARS-CoV-2 antibodies; Type 1 diabetes; Autoimmunity

向作者/读者索取更多资源

The study aimed to assess the relationship between SARS-CoV-2 infection and autoimmunity in type 1 diabetes (T1D) and the frequency of SARS-CoV-2 antibodies in newly diagnosed T1D patients. The results showed that none of the patients who contracted SARS-CoV-2 during the pandemic period tested positive for T1D autoantibodies. The frequency of SARS-CoV-2 antibodies in newly diagnosed T1D patients was not significantly different from healthy individuals.
AimsTo evaluate the relationship between SARS-CoV-2 infection and autoimmunity in type 1 diabetes (T1D) and SARS-CoV-2 antibodies frequency at diagnosis of T1D during pandemic.MethodsThe presence of T1D-specific autoimmunity was evaluated in a cohort of 99 children and adolescents without diabetes that contracted SARS-CoV-2 infection. Moreover, the frequency of IgM- and IgG-SARS-CoV-2 antibodies was evaluated in 41 newly diagnosed T1D patients not yet vaccinated against SARS-CoV-2 disease, collected during the pandemic, compared to healthy subjects (CTRL).ResultsNone of the 99 patients that contracted SARS-CoV-2 infection during the pandemic period was found positive for T1D autoantibodies. The frequency of SARS-CoV-2 antibodies was not significantly different in patients newly diagnosed with T1D (12.2%), compared with CTRL (8.4%). Among SARS-CoV-2 antibody positive T1D patients, 80% were target of diabetes autoantibodies and 60% had another concomitant autoimmune disease. Among the CTRL subjects positive for SARS-CoV-2Abs (n = 10), none was found positive for T1D autoantibodies.ConclusionsThe results of the present study do not confirm, at least in the short term, a role of COVID-19 as a potential trigger of T1D autoimmunity and do not provide evidence of an increased frequency of SARS-CoV-2 antibodies in newly diagnosed T1D patients in comparison with healthy population.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据